JP2016513112A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016513112A5 JP2016513112A5 JP2015558195A JP2015558195A JP2016513112A5 JP 2016513112 A5 JP2016513112 A5 JP 2016513112A5 JP 2015558195 A JP2015558195 A JP 2015558195A JP 2015558195 A JP2015558195 A JP 2015558195A JP 2016513112 A5 JP2016513112 A5 JP 2016513112A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- heterocyclyl
- aryl
- heteroaryl
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 53
- 125000000623 heterocyclic group Chemical group 0.000 claims description 53
- 125000003118 aryl group Chemical group 0.000 claims description 52
- 125000001072 heteroaryl group Chemical group 0.000 claims description 48
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 45
- 125000000217 alkyl group Chemical group 0.000 claims description 42
- 230000004064 dysfunction Effects 0.000 claims description 15
- 229910052757 nitrogen Inorganic materials 0.000 claims description 14
- 229910052717 sulfur Inorganic materials 0.000 claims description 14
- 208000019901 Anxiety disease Diseases 0.000 claims description 13
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 12
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 12
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 12
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 12
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 10
- 125000002252 acyl group Chemical group 0.000 claims description 10
- 208000030159 metabolic disease Diseases 0.000 claims description 10
- 230000003169 placental effect Effects 0.000 claims description 10
- 230000029663 wound healing Effects 0.000 claims description 10
- 229910052760 oxygen Inorganic materials 0.000 claims description 9
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims description 8
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 8
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 8
- -1 Heteroshi Lil Chemical group 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 102000004136 Vasopressin Receptors Human genes 0.000 claims description 7
- 108090000643 Vasopressin Receptors Proteins 0.000 claims description 7
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 6
- 125000003342 alkenyl group Chemical group 0.000 claims description 6
- 125000000304 alkynyl group Chemical group 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 6
- 125000001188 haloalkyl group Chemical group 0.000 claims description 6
- 125000005842 heteroatom Chemical group 0.000 claims description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 5
- 208000004998 Abdominal Pain Diseases 0.000 claims description 5
- 208000007848 Alcoholism Diseases 0.000 claims description 5
- 206010003805 Autism Diseases 0.000 claims description 5
- 208000020706 Autistic disease Diseases 0.000 claims description 5
- 208000008035 Back Pain Diseases 0.000 claims description 5
- 208000017164 Chronobiology disease Diseases 0.000 claims description 5
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 claims description 5
- 206010010774 Constipation Diseases 0.000 claims description 5
- 206010061974 Gastrointestinal obstruction Diseases 0.000 claims description 5
- 208000010496 Heart Arrest Diseases 0.000 claims description 5
- 208000032843 Hemorrhage Diseases 0.000 claims description 5
- 206010021718 Induced labour Diseases 0.000 claims description 5
- 206010061218 Inflammation Diseases 0.000 claims description 5
- 208000001456 Jet Lag Syndrome Diseases 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 208000008589 Obesity Diseases 0.000 claims description 5
- 208000001132 Osteoporosis Diseases 0.000 claims description 5
- 208000002193 Pain Diseases 0.000 claims description 5
- 208000018525 Postpartum Hemorrhage Diseases 0.000 claims description 5
- 206010040070 Septic Shock Diseases 0.000 claims description 5
- 208000006011 Stroke Diseases 0.000 claims description 5
- 208000036064 Surgical Blood Loss Diseases 0.000 claims description 5
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 5
- 206010047141 Vasodilatation Diseases 0.000 claims description 5
- 230000003187 abdominal effect Effects 0.000 claims description 5
- 206010001584 alcohol abuse Diseases 0.000 claims description 5
- 208000025746 alcohol use disease Diseases 0.000 claims description 5
- 208000034158 bleeding Diseases 0.000 claims description 5
- 230000000740 bleeding effect Effects 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 238000002680 cardiopulmonary resuscitation Methods 0.000 claims description 5
- 206010008118 cerebral infarction Diseases 0.000 claims description 5
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 5
- 230000008602 contraction Effects 0.000 claims description 5
- 206010012601 diabetes mellitus Diseases 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 5
- 208000026278 immune system disease Diseases 0.000 claims description 5
- 230000001771 impaired effect Effects 0.000 claims description 5
- 208000015181 infectious disease Diseases 0.000 claims description 5
- 230000004054 inflammatory process Effects 0.000 claims description 5
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 claims description 5
- 230000006651 lactation Effects 0.000 claims description 5
- 208000004396 mastitis Diseases 0.000 claims description 5
- 229960002715 nicotine Drugs 0.000 claims description 5
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 5
- 235000020824 obesity Nutrition 0.000 claims description 5
- 230000036407 pain Effects 0.000 claims description 5
- 208000030761 polycystic kidney disease Diseases 0.000 claims description 5
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 5
- 230000036303 septic shock Effects 0.000 claims description 5
- 230000035939 shock Effects 0.000 claims description 5
- 208000011117 substance-related disease Diseases 0.000 claims description 5
- 208000011580 syndromic disease Diseases 0.000 claims description 5
- 230000009529 traumatic brain injury Effects 0.000 claims description 5
- 230000024883 vasodilation Effects 0.000 claims description 5
- ABADUMLIAZCWJD-UHFFFAOYSA-N 1,3-dioxole Chemical group C1OC=CO1 ABADUMLIAZCWJD-UHFFFAOYSA-N 0.000 claims description 4
- 208000008811 Agoraphobia Diseases 0.000 claims description 4
- 241000790917 Dioxys <bee> Species 0.000 claims description 4
- 206010057671 Female sexual dysfunction Diseases 0.000 claims description 4
- 208000011688 Generalised anxiety disease Diseases 0.000 claims description 4
- 206010057672 Male sexual dysfunction Diseases 0.000 claims description 4
- 150000001204 N-oxides Chemical class 0.000 claims description 4
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 4
- 208000000810 Separation Anxiety Diseases 0.000 claims description 4
- 206010041250 Social phobia Diseases 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 125000002619 bicyclic group Chemical group 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 208000029364 generalized anxiety disease Diseases 0.000 claims description 4
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 4
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 4
- 125000002950 monocyclic group Chemical group 0.000 claims description 4
- 208000019906 panic disease Diseases 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 208000019899 phobic disease Diseases 0.000 claims description 4
- 125000003367 polycyclic group Chemical group 0.000 claims description 4
- 208000028173 post-traumatic stress disease Diseases 0.000 claims description 4
- 229920006395 saturated elastomer Polymers 0.000 claims description 4
- 125000003003 spiro group Chemical group 0.000 claims description 4
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 4
- 206010013654 Drug abuse Diseases 0.000 claims description 3
- 206010043903 Tobacco abuse Diseases 0.000 claims description 3
- LRANPJDWHYRCER-UHFFFAOYSA-N 1,2-diazepine Chemical compound N1C=CC=CC=N1 LRANPJDWHYRCER-UHFFFAOYSA-N 0.000 claims description 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 claims description 2
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims description 2
- 230000008878 coupling Effects 0.000 claims description 2
- 238000010168 coupling process Methods 0.000 claims description 2
- 238000005859 coupling reaction Methods 0.000 claims description 2
- SFJGCXYXEFWEBK-UHFFFAOYSA-N oxazepine Chemical compound O1C=CC=CC=N1 SFJGCXYXEFWEBK-UHFFFAOYSA-N 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 201000009032 substance abuse Diseases 0.000 claims description 2
- 231100000736 substance abuse Toxicity 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 13
- 0 C*(C*(C)N(**I)CC1)CN1C(*C[Al]I)=O Chemical compound C*(C*(C)N(**I)CC1)CN1C(*C[Al]I)=O 0.000 description 21
- 238000000034 method Methods 0.000 description 7
- RJWLATJMEFHYBV-UHFFFAOYSA-N Cc(cc1CCCC2)ccc1N2C(C1CCNCC1)=O Chemical compound Cc(cc1CCCC2)ccc1N2C(C1CCNCC1)=O RJWLATJMEFHYBV-UHFFFAOYSA-N 0.000 description 5
- NLGPZDSNMGVQQS-UHFFFAOYSA-N O=C(C1CCNCC1)N(CC1CC1)c(cc1)ccc1Cl Chemical compound O=C(C1CCNCC1)N(CC1CC1)c(cc1)ccc1Cl NLGPZDSNMGVQQS-UHFFFAOYSA-N 0.000 description 3
- RXYPXQSKLGGKOL-UHFFFAOYSA-N CN1CCN(C)CC1 Chemical compound CN1CCN(C)CC1 RXYPXQSKLGGKOL-UHFFFAOYSA-N 0.000 description 2
- SMWUDAKKCDQTPV-UHFFFAOYSA-N CN1CN(C)CC1 Chemical compound CN1CN(C)CC1 SMWUDAKKCDQTPV-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- ZRZKFJJSTOCTEY-UHFFFAOYSA-N C(C1CC1)[n]1c(N(CC2)CCC22OCc3c2cccc3)nc2c1cccc2 Chemical compound C(C1CC1)[n]1c(N(CC2)CCC22OCc3c2cccc3)nc2c1cccc2 ZRZKFJJSTOCTEY-UHFFFAOYSA-N 0.000 description 1
- LTOLADFOKOUXIC-UHFFFAOYSA-N CC(C)c1cc(C(N(CC2)CCC22OCc3ccccc23)=O)n[o]1 Chemical compound CC(C)c1cc(C(N(CC2)CCC22OCc3ccccc23)=O)n[o]1 LTOLADFOKOUXIC-UHFFFAOYSA-N 0.000 description 1
- XVIVXTHUBGHWOW-UHFFFAOYSA-N CC(N(C)c(cc1)ccc1C(N(CC1)CCC11OCc2ccccc12)=O)=O Chemical compound CC(N(C)c(cc1)ccc1C(N(CC1)CCC11OCc2ccccc12)=O)=O XVIVXTHUBGHWOW-UHFFFAOYSA-N 0.000 description 1
- UIRYQKABKAYFSR-UHFFFAOYSA-N CC(NC(C=C1)=CCC1C(N(CC1)CCC11OCc2ccccc12)=O)=O Chemical compound CC(NC(C=C1)=CCC1C(N(CC1)CCC11OCc2ccccc12)=O)=O UIRYQKABKAYFSR-UHFFFAOYSA-N 0.000 description 1
- WSIJEFCABFYEBZ-UHFFFAOYSA-N CCC(N(C(CC1)CCN1C(C(C)(C)c(cc1)ccc1Cl)=O)c1ccccc1)=O Chemical compound CCC(N(C(CC1)CCN1C(C(C)(C)c(cc1)ccc1Cl)=O)c1ccccc1)=O WSIJEFCABFYEBZ-UHFFFAOYSA-N 0.000 description 1
- YUAJTZMHKPTFBX-UHFFFAOYSA-N CCC(N(C(CC1)CCN1C(C1(CC1)c(cc1)ccc1Cl)=O)c1ccccc1)=O Chemical compound CCC(N(C(CC1)CCN1C(C1(CC1)c(cc1)ccc1Cl)=O)c1ccccc1)=O YUAJTZMHKPTFBX-UHFFFAOYSA-N 0.000 description 1
- HSSQLKVXNFBUKZ-UHFFFAOYSA-N CCC(N(C(CC1)CCN1c(cc1)ncc1C#N)c1ccccc1)=O Chemical compound CCC(N(C(CC1)CCN1c(cc1)ncc1C#N)c1ccccc1)=O HSSQLKVXNFBUKZ-UHFFFAOYSA-N 0.000 description 1
- SRTTXFVDNUNCOF-UHFFFAOYSA-N CCC(N(C(CC1)CCN1c(nccc1)c1C#N)c1ccccc1)=O Chemical compound CCC(N(C(CC1)CCN1c(nccc1)c1C#N)c1ccccc1)=O SRTTXFVDNUNCOF-UHFFFAOYSA-N 0.000 description 1
- WTAKRSGRINEDHG-UHFFFAOYSA-N CCC(N(C(CC1)CCN1c1c(C(F)(F)F)cccn1)c1ccccc1)=O Chemical compound CCC(N(C(CC1)CCN1c1c(C(F)(F)F)cccn1)c1ccccc1)=O WTAKRSGRINEDHG-UHFFFAOYSA-N 0.000 description 1
- PMCBDBWCQQBSRJ-UHFFFAOYSA-N CCC(N(C1CCNCC1)c1ccccc1)=O Chemical compound CCC(N(C1CCNCC1)c1ccccc1)=O PMCBDBWCQQBSRJ-UHFFFAOYSA-N 0.000 description 1
- FMNHXBPKXBFMAA-UHFFFAOYSA-N CN(CCOc1c2)c1ccc2C(N(CC1)CCC11OCc2ccccc12)=O Chemical compound CN(CCOc1c2)c1ccc2C(N(CC1)CCC11OCc2ccccc12)=O FMNHXBPKXBFMAA-UHFFFAOYSA-N 0.000 description 1
- SBQATARWUJUBPX-UHFFFAOYSA-N CN(c(cccc1)c1C(N(CC1)CCC11OCc2c1cccc2)=NC1)C1=O Chemical compound CN(c(cccc1)c1C(N(CC1)CCC11OCc2c1cccc2)=NC1)C1=O SBQATARWUJUBPX-UHFFFAOYSA-N 0.000 description 1
- SKCMLODCICUUOQ-UHFFFAOYSA-N COc1cc(C(N(CC2)CCC22OCc3ccccc23)=O)ccc1N Chemical compound COc1cc(C(N(CC2)CCC22OCc3ccccc23)=O)ccc1N SKCMLODCICUUOQ-UHFFFAOYSA-N 0.000 description 1
- LNPXTCCVJYMXBF-UHFFFAOYSA-N C[n]1ncc2c1Nc(cccc1)c1N(CC(N(CC1)CCC11OCc3ccccc13)=O)C2 Chemical compound C[n]1ncc2c1Nc(cccc1)c1N(CC(N(CC1)CCC11OCc3ccccc13)=O)C2 LNPXTCCVJYMXBF-UHFFFAOYSA-N 0.000 description 1
- LAOXUPUGNVPTRV-UHFFFAOYSA-N Cc(cc1CCCC2)ccc1N2C(C(CC1)CCN1c(nccc1)c1C#N)=O Chemical compound Cc(cc1CCCC2)ccc1N2C(C(CC1)CCN1c(nccc1)c1C#N)=O LAOXUPUGNVPTRV-UHFFFAOYSA-N 0.000 description 1
- PSFVFBLXKHUEEX-UHFFFAOYSA-N Cc(cc1CCCC2)ccc1N2C(C(CC1)CCN1c1ncnc(cc2)c1cc2F)=O Chemical compound Cc(cc1CCCC2)ccc1N2C(C(CC1)CCN1c1ncnc(cc2)c1cc2F)=O PSFVFBLXKHUEEX-UHFFFAOYSA-N 0.000 description 1
- QWVGKYWNOKOFNN-UHFFFAOYSA-N Cc(cccc1)c1O Chemical compound Cc(cccc1)c1O QWVGKYWNOKOFNN-UHFFFAOYSA-N 0.000 description 1
- YLYQQGILJFMORS-UHFFFAOYSA-N Cc(nc1)cnc1C(N(CC1)CCC11OCc2ccccc12)=O Chemical compound Cc(nc1)cnc1C(N(CC1)CCC11OCc2ccccc12)=O YLYQQGILJFMORS-UHFFFAOYSA-N 0.000 description 1
- PYUFGCMIHHQLHW-UHFFFAOYSA-N Cc1cc(C(N(C2)c3ccccc3Nc3c2cn[n]3C)=O)ccc1CNC(N(CC1)CCC11OCc2ccccc12)=O Chemical compound Cc1cc(C(N(C2)c3ccccc3Nc3c2cn[n]3C)=O)ccc1CNC(N(CC1)CCC11OCc2ccccc12)=O PYUFGCMIHHQLHW-UHFFFAOYSA-N 0.000 description 1
- YJVFUQWBLDZMAP-UHFFFAOYSA-N Cc1cc(C(N(CC2)CCC22OCc3ccccc23)=O)n[o]1 Chemical compound Cc1cc(C(N(CC2)CCC22OCc3ccccc23)=O)n[o]1 YJVFUQWBLDZMAP-UHFFFAOYSA-N 0.000 description 1
- URDTZPOKQQSOEG-UHFFFAOYSA-N Cc1nc(ccc(C(N(CC2)CCC22OCc3ccccc23)=O)c2)c2[o]1 Chemical compound Cc1nc(ccc(C(N(CC2)CCC22OCc3ccccc23)=O)c2)c2[o]1 URDTZPOKQQSOEG-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- YATAWSYYTTYWNN-UHFFFAOYSA-N N#Cc(cc1)ccc1C(N(CC1)CCC11OCc2ccccc12)=O Chemical compound N#Cc(cc1)ccc1C(N(CC1)CCC11OCc2ccccc12)=O YATAWSYYTTYWNN-UHFFFAOYSA-N 0.000 description 1
- UADSKPGDYQIUDK-UHFFFAOYSA-N N#Cc(nc1)ccc1C(N(CC1)CCC11OCc2ccccc12)=O Chemical compound N#Cc(nc1)ccc1C(N(CC1)CCC11OCc2ccccc12)=O UADSKPGDYQIUDK-UHFFFAOYSA-N 0.000 description 1
- BJUXPLKGVTWKIV-UHFFFAOYSA-N NS(c(cc1)ccc1C(N(CC1)CCC11OCc2ccccc12)=O)(=O)=O Chemical compound NS(c(cc1)ccc1C(N(CC1)CCC11OCc2ccccc12)=O)(=O)=O BJUXPLKGVTWKIV-UHFFFAOYSA-N 0.000 description 1
- WZPAVZZIWRYXSN-UHFFFAOYSA-N Nc([n](-c(cc1)ccc1Cl)nc1CNC(N(CC2)CCC22OCc3ccccc23)=O)c1-c1ccccc1 Chemical compound Nc([n](-c(cc1)ccc1Cl)nc1CNC(N(CC2)CCC22OCc3ccccc23)=O)c1-c1ccccc1 WZPAVZZIWRYXSN-UHFFFAOYSA-N 0.000 description 1
- JIUFFCUFCZKLCQ-UHFFFAOYSA-N Nc([n](-c(cc1Cl)ccc1Cl)nc1CNC(N(CC2)CCC22OCc3ccccc23)=O)c1-c1ccccc1 Chemical compound Nc([n](-c(cc1Cl)ccc1Cl)nc1CNC(N(CC2)CCC22OCc3ccccc23)=O)c1-c1ccccc1 JIUFFCUFCZKLCQ-UHFFFAOYSA-N 0.000 description 1
- RJQMFFVVKPSHSS-UHFFFAOYSA-N Nc(cc1)ccc1C(N(CC1)CCC11OCc2ccccc12)=O Chemical compound Nc(cc1)ccc1C(N(CC1)CCC11OCc2ccccc12)=O RJQMFFVVKPSHSS-UHFFFAOYSA-N 0.000 description 1
- WKTWMONGQHTYLO-UHFFFAOYSA-N O=C(C(C1)c2cccc3cccc1c23)N(CC1)CCC11OCc2ccccc12 Chemical compound O=C(C(C1)c2cccc3cccc1c23)N(CC1)CCC11OCc2ccccc12 WKTWMONGQHTYLO-UHFFFAOYSA-N 0.000 description 1
- MDAYVTLGVGPPLA-UHFFFAOYSA-N O=C(C(CC1)CCN1c1ncccc1)N(CCCCc1c2)c1ccc2Cl Chemical compound O=C(C(CC1)CCN1c1ncccc1)N(CCCCc1c2)c1ccc2Cl MDAYVTLGVGPPLA-UHFFFAOYSA-N 0.000 description 1
- NJJSTINQMDWGFK-UHFFFAOYSA-N O=C(C(CC1)CCN1c1ncnc(cc2)c1cc2F)N(CC1CC1)c(cc1)ccc1Cl Chemical compound O=C(C(CC1)CCN1c1ncnc(cc2)c1cc2F)N(CC1CC1)c(cc1)ccc1Cl NJJSTINQMDWGFK-UHFFFAOYSA-N 0.000 description 1
- WOMVRKOBQYSDQP-UHFFFAOYSA-N O=C(C(F)(F)F)Nc(cc1)ccc1C(N(CC1)CCC11OCc2ccccc12)=O Chemical compound O=C(C(F)(F)F)Nc(cc1)ccc1C(N(CC1)CCC11OCc2ccccc12)=O WOMVRKOBQYSDQP-UHFFFAOYSA-N 0.000 description 1
- IZJKWDHPFHYJKX-UHFFFAOYSA-N O=C(C1CCCC1)Nc(cc1)ccc1C(N(CC1)CCC11OCc2ccccc12)=O Chemical compound O=C(C1CCCC1)Nc(cc1)ccc1C(N(CC1)CCC11OCc2ccccc12)=O IZJKWDHPFHYJKX-UHFFFAOYSA-N 0.000 description 1
- SBUIRONVGMZEBJ-UHFFFAOYSA-N O=C(N(CC1CC1)c1ccccc1)N(CC1)CCC11OCc2c1cccc2 Chemical compound O=C(N(CC1CC1)c1ccccc1)N(CC1)CCC11OCc2c1cccc2 SBUIRONVGMZEBJ-UHFFFAOYSA-N 0.000 description 1
- XNPSGXZQLVWXPQ-UHFFFAOYSA-N O=C(c(cc1)ccc1F)N(CC1)CCC11OCc2ccccc12 Chemical compound O=C(c(cc1)ccc1F)N(CC1)CCC11OCc2ccccc12 XNPSGXZQLVWXPQ-UHFFFAOYSA-N 0.000 description 1
- BIPKJIWRKBSMNO-UHFFFAOYSA-N O=C(c1cc(-c2ccccc2)c(C(F)(F)F)[s]1)N(CC1)CCC11OCc2ccccc12 Chemical compound O=C(c1cc(-c2ccccc2)c(C(F)(F)F)[s]1)N(CC1)CCC11OCc2ccccc12 BIPKJIWRKBSMNO-UHFFFAOYSA-N 0.000 description 1
- LXKLEGSBXXJKNU-UHFFFAOYSA-N O=C(c1cc(cc(cc2)Cl)c2[nH]1)N(CC1)CCC11OCc2ccccc12 Chemical compound O=C(c1cc(cc(cc2)Cl)c2[nH]1)N(CC1)CCC11OCc2ccccc12 LXKLEGSBXXJKNU-UHFFFAOYSA-N 0.000 description 1
- BLYHJBADAXRGOB-UHFFFAOYSA-N O=C(c1ccc(C(F)(F)F)nc1)N(CC1)CCC11OCc2ccccc12 Chemical compound O=C(c1ccc(C(F)(F)F)nc1)N(CC1)CCC11OCc2ccccc12 BLYHJBADAXRGOB-UHFFFAOYSA-N 0.000 description 1
- OKAADSKCYMGFPL-UHFFFAOYSA-N O=C(c1ccccc1)N(CC1)CCC11OCc2ccccc12 Chemical compound O=C(c1ccccc1)N(CC1)CCC11OCc2ccccc12 OKAADSKCYMGFPL-UHFFFAOYSA-N 0.000 description 1
- MKVLMBJFYVMZGQ-UHFFFAOYSA-N O=S(c1cc2ccccc2[s]1)(N(CC1)CCC11OCc2c1cccc2)=O Chemical compound O=S(c1cc2ccccc2[s]1)(N(CC1)CCC11OCc2c1cccc2)=O MKVLMBJFYVMZGQ-UHFFFAOYSA-N 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361765956P | 2013-02-18 | 2013-02-18 | |
| US201361765968P | 2013-02-18 | 2013-02-18 | |
| US61/765,968 | 2013-02-18 | ||
| US61/765,956 | 2013-02-18 | ||
| PCT/US2014/016881 WO2014127350A1 (en) | 2013-02-18 | 2014-02-18 | Modulators of vasopressin receptors with therapeutic potential |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016513112A JP2016513112A (ja) | 2016-05-12 |
| JP2016513112A5 true JP2016513112A5 (https=) | 2017-03-23 |
Family
ID=51354614
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015558195A Pending JP2016513112A (ja) | 2013-02-18 | 2014-02-18 | 治療的潜在能力を有するバソプレッシン受容体のモジュレーター |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20150376198A1 (https=) |
| EP (1) | EP2956441A4 (https=) |
| JP (1) | JP2016513112A (https=) |
| CN (1) | CN105263910A (https=) |
| CA (1) | CA2901577A1 (https=) |
| WO (1) | WO2014127350A1 (https=) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012003436A1 (en) | 2010-07-01 | 2012-01-05 | Azevan Pharmaceuticals, Inc. | Methods for treating post traumatic stress disorder |
| MX350443B (es) | 2012-05-17 | 2017-09-06 | Genentech Inc | Proceso para hacer compuestos de aminoácidos. |
| HRP20200992T1 (hr) | 2012-05-17 | 2020-10-16 | Genentech, Inc. | Amorfni oblik pirimidinil-ciklopentanskog spoja koji inhibira akt, te njegovi pripravci i postupci |
| CN104471070B (zh) | 2012-05-17 | 2018-09-25 | 基因泰克公司 | 制备羟基化环戊并嘧啶化合物和其盐的方法 |
| RU2014151017A (ru) | 2012-05-17 | 2016-07-10 | Аррэй Байофарма Инк. | Способ получения гидроксилированных циклопентилпиримидинов |
| AU2013262505B2 (en) | 2012-05-17 | 2017-09-21 | Array Biopharma Inc. | Process for making hydroxylated cyclopentylpyrimidine compounds |
| US9527835B2 (en) | 2014-02-13 | 2016-12-27 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
| SI3105218T1 (sl) | 2014-02-13 | 2019-11-29 | Incyte Corp | Ciklopropilamini kot inhibitorji LSD1 |
| MX373103B (es) | 2014-02-13 | 2020-04-17 | Incyte Holdings Corp | Ciclopropilaminas como inhibidores de desmetilasa específica de lisina 1 (lsd1). |
| EP3105219B9 (en) | 2014-02-13 | 2018-10-03 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
| NZ724718A (en) | 2014-03-28 | 2023-04-28 | Azevan Pharmaceuticals Inc | Compositions and methods for treating neurodegenerative diseases |
| TWI687419B (zh) | 2014-07-10 | 2020-03-11 | 美商英塞特公司 | 作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪 |
| WO2016007722A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| WO2016007727A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| TW201613925A (en) | 2014-07-10 | 2016-04-16 | Incyte Corp | Imidazopyrazines as LSD1 inhibitors |
| WO2016075181A1 (en) * | 2014-11-14 | 2016-05-19 | F. Hoffmann-La Roche Ag | Spiro-thiazolones |
| WO2016086357A1 (en) | 2014-12-02 | 2016-06-09 | Merck Sharp & Dohme Corp. | Methyl oxazole orexin receptor antagonists |
| EP3277689B1 (en) | 2015-04-03 | 2019-09-04 | Incyte Corporation | Heterocyclic compounds as lsd1 inhibitors |
| WO2017012502A1 (en) | 2015-07-17 | 2017-01-26 | Sunshine Lake Pharma Co., Ltd. | Substituted quinazoline compounds and preparation and uses thereof |
| LT3334709T (lt) | 2015-08-12 | 2025-03-10 | Incyte Holdings Corporation | Lsd1 inhibitoriaus druskos |
| CN105622528B (zh) * | 2016-02-01 | 2017-12-15 | 新乡医学院第一附属医院 | 一种治疗肺动脉高压的化合物及其应用 |
| JP6999574B2 (ja) | 2016-04-22 | 2022-01-18 | インサイト・コーポレイション | Ｌｓｄ１阻害剤の製剤 |
| CN109414420A (zh) * | 2016-05-04 | 2019-03-01 | 百时美施贵宝公司 | 吲哚胺2,3-双加氧酶的抑制剂及其使用方法 |
| JP2019516682A (ja) * | 2016-05-04 | 2019-06-20 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | インドールアミン２，３−ジオキシゲナーゼ阻害剤およびその使用方法 |
| US20190298705A1 (en) | 2016-06-08 | 2019-10-03 | Glaxosmithkline Intellectual Property Development Limited | Chemical Compounds |
| JOP20190050A1 (ar) | 2016-09-23 | 2019-03-20 | Bial Portela & C? S A | مثبطات دوبامين-b-هيدروكسيلاز تخترق حاجز المخ الدموي |
| JOP20190072A1 (ar) | 2016-10-13 | 2019-04-07 | Glaxosmithkline Ip Dev Ltd | مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم |
| NZ797702A (en) | 2017-03-13 | 2026-03-27 | Lundbeck La Jolla Research Center Inc | Dual magl and faah inhibitors |
| WO2019003433A1 (ja) | 2017-06-30 | 2019-01-03 | 大塚製薬株式会社 | ベンゾアゼピン誘導体 |
| KR102765806B1 (ko) * | 2017-09-05 | 2025-02-10 | 블랙손 테라퓨틱스, 인크. | 바소프레신 수용체 길항제 및 그와 관련된 제품 및 방법 |
| WO2019055913A1 (en) * | 2017-09-15 | 2019-03-21 | Azevan Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS FOR TREATMENT OF BRAIN INJURY |
| HRP20250272T1 (hr) | 2017-10-19 | 2025-04-25 | Teijin Pharma Limited | Derivati benzimidazola i njihova uporaba |
| CN111479812A (zh) | 2017-12-04 | 2020-07-31 | 巴尔-波特拉及康邦亚股份有限公司 | 多巴胺-b-羟化酶抑制剂 |
| HU231206B1 (hu) | 2017-12-15 | 2021-10-28 | Richter Gedeon Nyrt. | Triazolobenzazepinek |
| TW201938171A (zh) | 2017-12-15 | 2019-10-01 | 匈牙利商羅特格登公司 | 作為血管升壓素Ｖ１ａ受體拮抗劑之三環化合物 |
| CA3045644C (en) | 2018-06-13 | 2024-01-16 | Pfizer Inc. | Glp-1 receptor agonists and uses thereof |
| WO2020047198A1 (en) | 2018-08-31 | 2020-03-05 | Incyte Corporation | Salts of an lsd1 inhibitor and processes for preparing the same |
| JP7542538B2 (ja) | 2018-09-18 | 2024-08-30 | ニカング セラピューティクス， インコーポレイテッド | Ｓｒｃホモロジー－２ホスファターゼ阻害剤としての縮合三環式環誘導体 |
| JP7627343B2 (ja) * | 2020-11-26 | 2025-02-05 | シャンハイ ジェミンケア ファーマシューティカル カンパニー，リミティド | 新規ベンズアゼピンスピロ環式誘導体 |
| EP4291181A1 (en) * | 2021-02-12 | 2023-12-20 | The Scripps Research Institute | Small molecule activators of yap transcriptional activity for regenerative organ repair |
| US12018016B2 (en) | 2021-08-18 | 2024-06-25 | Amgen Inc. | Aryl sulfonyl (hydroxy) piperidines as CCR6 inhibitors |
| WO2023023534A2 (en) | 2021-08-18 | 2023-02-23 | Chemocentryx, Inc. | Aryl sulfonyl compounds as ccr6 inhibitors |
| CN118475583A (zh) * | 2021-10-26 | 2024-08-09 | 瓦索卡地亚公司 | Gpr39蛋白的拮抗剂 |
| CN114394931B (zh) * | 2022-01-30 | 2023-07-11 | 西安交通大学 | 具有血管舒张活性的单萜生物碱及其提取方法和应用 |
| TW202413352A (zh) | 2022-06-13 | 2024-04-01 | 日商模數探索股份有限公司 | 氮雜環烷基羰基環狀胺化合物 |
| WO2024050109A2 (en) * | 2022-09-02 | 2024-03-07 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Methods and compositions for controlling jet lag, chronotype, or circadian rhythm |
| JP2026500305A (ja) | 2022-12-16 | 2026-01-06 | アストラゼネカ・アクチエボラーグ | ２，６，９三置換プリン |
| WO2025224085A1 (en) * | 2024-04-23 | 2025-10-30 | Universitat De Barcelona | Compounds capable of acting on s1r as well as on seh and uses thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3607993A1 (de) * | 1986-03-11 | 1987-09-17 | Basf Ag | Verfahren zur herstellung von diaziridinen und produkte daraus |
| FR2624857B1 (fr) * | 1987-12-16 | 1991-03-22 | Irceba | Derives de nicotinoyl-piperazine, procede de preparation et utilisation en therapeutique |
| AU687953B2 (en) * | 1993-11-16 | 1998-03-05 | Merck & Co., Inc. | Piperidinylcamphorsulfonyl oxytocin antagonists |
| NZ329847A (en) * | 1996-06-29 | 1999-01-28 | Samjin Pharm Co Ltd | Piperazine derivatives and process for the preparation thereof |
| GB2326639A (en) * | 1997-06-18 | 1998-12-30 | Merck & Co Inc | Piperazine Oxytocin Receptor Antagonists |
| ES2125206B1 (es) * | 1997-07-21 | 1999-11-16 | Esteve Labor Dr | Derivados de acil-piperazinil-pirimidinas, su preparacion y su aplicacion como medicamentos. |
| EP1551811A1 (en) * | 2002-10-17 | 2005-07-13 | Amgen Inc. | Benzimidazole derivatives and their use as vanilloid receptor ligands |
| AR055831A1 (es) * | 2004-12-30 | 2007-09-12 | Janssen Pharmaceutica Nv | Pepirazinilureas y piperidinilureas como moduladores de hidrolasa de amida de acidos grasos |
| TW200815426A (en) * | 2006-06-28 | 2008-04-01 | Astrazeneca Ab | New pyridine analogues II 333 |
| US8071622B2 (en) * | 2006-12-08 | 2011-12-06 | Hoffman-La Roche Inc. | Indoles |
| WO2009019219A2 (en) * | 2007-08-03 | 2009-02-12 | Solvay (Société Anonyme) | Methods of using a solvent or a foam blowing agent |
| US20120172369A1 (en) * | 2009-09-14 | 2012-07-05 | Ting Pauline C | Inhibitors of diacylglycerol acyltransferase |
| WO2012024179A1 (en) * | 2010-08-18 | 2012-02-23 | Merck Sharp & Dohme Corp. | Substituted amide derivatives as dgat-1 inhibitors |
| WO2012158844A1 (en) * | 2011-05-17 | 2012-11-22 | Shionogi & Co., Ltd. | Heterocyclic compounds |
-
2014
- 2014-02-18 WO PCT/US2014/016881 patent/WO2014127350A1/en not_active Ceased
- 2014-02-18 CN CN201480021479.5A patent/CN105263910A/zh active Pending
- 2014-02-18 EP EP14751923.5A patent/EP2956441A4/en not_active Withdrawn
- 2014-02-18 CA CA2901577A patent/CA2901577A1/en not_active Abandoned
- 2014-02-18 JP JP2015558195A patent/JP2016513112A/ja active Pending
- 2014-02-18 US US14/768,735 patent/US20150376198A1/en not_active Abandoned
-
2017
- 2017-01-27 US US15/418,579 patent/US20170327512A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016513112A5 (https=) | ||
| JP7241856B2 (ja) | ビス第四級アンモニウム化合物及びその製造方法と使用 | |
| RU2020121152A (ru) | Твердые формы ингибитора калликреина плазмы и их соли | |
| JP2015506382A5 (https=) | ||
| JP2021508686A5 (https=) | ||
| RU2016151727A (ru) | Нейроактивные стероиды, композиции и их применения | |
| RU2016137524A (ru) | Амидные соединения для лечения опосредованных комплементом нарушений | |
| JP2017531020A5 (https=) | ||
| RU2018115569A (ru) | Оксаспиропроизводное, способ его получения и его применения в лекарственных средствах | |
| BR122017023795B1 (pt) | Metodo para preparaqao de composiçao farmaceutica | |
| RU2017145646A (ru) | Производное пиперидина, способ его получения и его фармацевтическое применение | |
| JP2011523412A5 (https=) | ||
| RU2014122335A (ru) | ХИНОЛИНКАРБОКСАМИДНЫЕ И ХИНОЛИНКАРБОНИТРИЛЬНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ mGluR2-НЕГАТИВНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ, КОМПОЗИЦИИ И ИХ ПРИМЕНЕНИЕ | |
| RU2018139276A (ru) | Полиморфные модификации n-[(3-фтор-4-метоксипиридин-2-ил)метил]-3-(метоксиметил)-1-({ 4-[(2-оксопиридин-1-ил)метил]фенил} метил)пиразол-4-карбоксамида и их соли | |
| RU2015143466A (ru) | Нейроактивные стероиды и способы их применения | |
| JP2020507589A5 (https=) | ||
| JP2016527217A5 (https=) | ||
| JP2019515908A5 (https=) | ||
| JP2015531764A5 (https=) | ||
| JP2019529460A5 (https=) | ||
| KR101747486B1 (ko) | 동통 치료제 | |
| JP2014529584A5 (https=) | ||
| WO2024099434A1 (zh) | 葫芦脲类化合物及其医药用途 | |
| CN102653539B (zh) | 一种抗血小板聚集化合物及其药物组合 | |
| RU2002102076A (ru) | Фармацевтическая композиция, содержащая сибутрамин и орлистат |